Business context and reporting period
Filing identity: The supplied metadata names SOLESENCE, INC., but the filing itself is Nanophase Technologies Corporation’s unaudited Form 10-Q for the quarter ended March 31, 2014. Confirm the company and filing match before relying on this summary.
Nanophase develops and manufactures engineered nano- and sub-micron materials for personal care, coatings, polishing, and other applications. Its common stock traded on OTCQB under NANX. Financial statement amounts below are in thousands of dollars, except per-share data.
Financial performance and liquidity
| Metric | Q1 2014 | Q1 2013 / comparison |
|---|---|---|
| Total revenue | $2,585 | $2,979; down 13% |
| Gross profit / margin | $708 / 27.4% | $906 / 30.4% |
| Operating loss | $(427) | $(483) |
| Net loss | $(429); $(0.02) per share | $(484); $(0.02) per share |
| Cash used in operations | $(1,068) | $(429) |
- Product revenue was $2,576, versus $2,976; other revenue was $9, versus $3.
- R&D expense was $337 (down from $429); selling, general and administrative expense was $798 (down from $960). Operating margin was approximately (16.5%), compared with (16.2%).
- Cash and cash equivalents were $2,148 at March 31, 2014, versus $3,276 at year-end 2013; an additional $30 of investments was pledged as collateral. Combined cash and investments were $2,178.
- Current assets were $4,489 and current liabilities $1,044. Total liabilities were $1,838. Capital lease obligations totaled $34; management reported no debt.
- Cash fell $1,128 during the quarter. Investing activities used $53, including $30 of equipment and leasehold-improvement purchases; financing activities used $7.
Material changes versus prior comparable period
Revenue and gross profit declined year over year, but operating and net losses narrowed as operating expenses fell. Operating cash use increased substantially, primarily because receivables rose from an unusually low year-end 2013 balance. Receivables were $1,130 at March 31, 2014, versus $52 at December 31, 2013. Three customers represented approximately 80%, 6%, and 2% of Q1 revenue, making customer concentration a significant exposure.
Outlook, commentary, and risks
- No formal earnings or revenue guidance is provided. Management expected growth in customer adoption in 2014 and beyond, anticipated R&D and SG&A to remain near Q1 levels and below 2013 levels, and forecast $200–$250 of capital spending for the remainder of 2014 for currently known needs, potentially more if other projects succeed.
- Management said cash on hand and operating cash were expected to fund plans through 2014, while noting that future capital needs depend on customer acceptance, development progress, and manufacturing requirements. Additional financing might be unavailable or dilutive.
- BASF was the largest customer, and supply agreements give it potential technology-transfer and equipment-purchase rights upon specified triggers. A key covenant trigger includes trailing-12-month earnings below zero together with cash, cash equivalents, and certain investments below $1 million; acceleration of debt exceeding $10 million is another stated trigger. The company reported approximately $2.2 million of cash and investments and no debt at quarter-end.
- Management warned that a BASF-triggered transfer could cause significant revenue loss and take more than 12 months to replace affected capacity. Rare-earth supply and cerium-oxide costs, ability to pass cost increases through, uncertain demand, and reliance on major customers were also identified risks.
- Net operating loss carryforwards were approximately $79 million, but use may be limited and some may expire. Management reported effective disclosure controls, no material change in internal control over financial reporting, and no legal proceedings.
Key facts for investors to verify
- Resolve the mismatch between the requested issuer, SOLESENCE, INC., and the actual filing issuer, Nanophase Technologies Corporation.
- Review subsequent filings for revenue trends, customer concentration, and the status of BASF supply agreements and covenant triggers.
- Assess whether operating cash use and receivables collection support management’s 2014 liquidity expectations and planned capital spending.
- Check progress and commercial demand for newer applications, and the exposure of margins to product mix, manufacturing utilization, and raw-material costs.
- Confirm the availability and potential limitations of tax-loss carryforwards and any financing needs.